Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 308.59M | 295.84M | 294.95M | 186.23M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.87,"profit":true},{"date":"2022-12-31","value":95.58,"profit":true},{"date":"2023-12-31","value":60.35,"profit":true}] | |
Cost of Revenue | 186.18M | 173.95M | 185.94M | 119.25M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.43,"profit":true},{"date":"2022-12-31","value":99.87,"profit":true},{"date":"2023-12-31","value":64.05,"profit":true}] | |
Gross Profit | 122.41M | 121.89M | 109.01M | 66.98M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.58,"profit":true},{"date":"2022-12-31","value":89.06,"profit":true},{"date":"2023-12-31","value":54.72,"profit":true}] | |
Gross Margin | 39.67% | 41.20% | 36.96% | 35.97% | [{"date":"2020-12-31","value":96.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.71,"profit":true},{"date":"2023-12-31","value":87.3,"profit":true}] | |
Operating Expenses | 125.87M | 134.76M | 129.11M | 75.70M | [{"date":"2020-12-31","value":93.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.81,"profit":true},{"date":"2023-12-31","value":56.18,"profit":true}] | |
Operating Income | (3.87M) | (15.31M) | (21.48M) | (8.72M) | [{"date":"2020-12-31","value":-386900000,"profit":false},{"date":"2021-12-31","value":-1531300000,"profit":false},{"date":"2022-12-31","value":-2148200000,"profit":false},{"date":"2023-12-31","value":-872100000,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | (8.95M) | (81.21M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-895300000,"profit":false},{"date":"2023-12-31","value":-8120700000,"profit":false}] | |
Pre-Tax Income | (20.60M) | (30.06M) | (31.34M) | (92.74M) | [{"date":"2020-12-31","value":-2059600000,"profit":false},{"date":"2021-12-31","value":-3006100000,"profit":false},{"date":"2022-12-31","value":-3133900000,"profit":false},{"date":"2023-12-31","value":-9273600000,"profit":false}] | |
Income Taxes | 561.00K | 1.09M | 1.15M | (525.00K) | [{"date":"2020-12-31","value":48.74,"profit":true},{"date":"2021-12-31","value":94.44,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-45.61,"profit":false}] | |
Income After Taxes | - | - | (32.49M) | (92.21M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-3249000000,"profit":false},{"date":"2023-12-31","value":-9221100000,"profit":false}] | |
Income From Continuous Operations | - | - | (44.19M) | (49.29M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-4419200000,"profit":false},{"date":"2023-12-31","value":-4929100000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (21.16M) | (31.15M) | (32.49M) | (93.26M) | [{"date":"2020-12-31","value":-2115700000,"profit":false},{"date":"2021-12-31","value":-3114800000,"profit":false},{"date":"2022-12-31","value":-3249000000,"profit":false},{"date":"2023-12-31","value":-9326100000,"profit":false}] | |
EPS (Diluted) | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
CAMP | |
---|---|
Current Ratio | 1.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CAMP | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CAMP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 5.91 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -4.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CAMP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
CAMP4 THERAPEUTICS CORPORATION (CAMP) share price today is $6.9
Yes, Indians can buy shares of CAMP4 THERAPEUTICS CORPORATION (CAMP) on Vested. To buy CAMP4 THERAPEUTICS CORPORATION from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CAMP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CAMP4 THERAPEUTICS CORPORATION (CAMP) via the Vested app. You can start investing in CAMP4 THERAPEUTICS CORPORATION (CAMP) with a minimum investment of $1.
You can invest in shares of CAMP4 THERAPEUTICS CORPORATION (CAMP) via Vested in three simple steps:
The 52-week high price of CAMP4 THERAPEUTICS CORPORATION (CAMP) is $12.3. The 52-week low price of CAMP4 THERAPEUTICS CORPORATION (CAMP) is $4.06.
The price-to-earnings (P/E) ratio of CAMP4 THERAPEUTICS CORPORATION (CAMP) is
The price-to-book (P/B) ratio of CAMP4 THERAPEUTICS CORPORATION (CAMP) is 0.00
The dividend yield of CAMP4 THERAPEUTICS CORPORATION (CAMP) is 0.00%
The market capitalization of CAMP4 THERAPEUTICS CORPORATION (CAMP) is
The stock symbol (or ticker) of CAMP4 THERAPEUTICS CORPORATION is CAMP